Sheel Biotech Board of Directors
Get the latest insights into the leadership at Sheel Biotech. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Satya Narayan Chandak | Chairman & Director |
| Mr. Divye Chandak | Managing Director |
| Mr. Sanjay Chandak | Executive Director |
| Mr. Mini Chadha | Non Executive Director |
| Mr. Ramesh Chandra Srivastava | Non Executive Director |
| Mr. Shyamsundar Bang | Non Executive Director |
| Mr. Atul Kumar | Non Executive Director |
Sheel Biotech Share price
SHEEL
81
1.00 (-1.22%)Last updated on 30 Oct, 2025 | 15:29 IST
BUYSELL
Today's High
82.00
Today's Low
78.50
52 Week Low
76.00
52 Week High
95.55
The current prices are delayed, login to your account for live prices
LoginSheel Biotech FAQs
The board at Sheel Biotech consists of experienced professionals, including Mr. Satya Narayan Chandak , Mr. Divye Chandak , and others, overseeing the company’s strategic and corporate governance.
Directors at Sheel Biotech are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Satya Narayan Chandak is the current chairman at Sheel Biotech.
Executive directors at Sheel Biotech are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Sheel Biotech adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Sheel Biotech, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.